Latest news with #TNG
Focus Malaysia
a day ago
- Business
- Focus Malaysia
TNG Digital launches Business Account to help even the smallest businesses grow with ease
TNG Digital Sdn Bhd has launched the TNG Digital Business Account which is designed to support micro-SMEs and gig workers with a zero-barrier solution to digitalise their operations, manage income, and grow their businesses securely, all from a mobile device. The launch was officiated by Deputy Domestic Trade and Cost of Living Minister Fuziah Salleh alongside TNG Digital CEO Alan Ni. This initiative marks a significant step forward in making digital financial tools more accessible to Malaysia's underserved and informal business communities. TNG Digital Business Account is a fully digital e-Wallet account issued by TNG Digital, an approved e-money issuer regulated by Bank Negara Malaysia. It requires no fees, no paperwork, and no minimum balance, designed for all types of small businesses including SMEs, microSMEs (MSMEs), hawkers, informal merchants, and gig workers, who are often excluded from traditional financial services. 'TNG Digital Business Account was built to address a clear gap. Although micro and small businesses contribute nearly 40% of GDP and support almost half of the nation's workforce, many still lack access to tools that help them scale and operate efficiently in a digital economy. 'This solution enables them to accept payment, manage transactions and grow their businesses efficiently through their mobile phones. 'For a long time, many micro and small businesses have had to make do without the right tools to manage their finances efficiently. 'With the TNG Digital Business Account, we're changing that by removing the barriers and allowing SMEs to open an account instantly, receive funds in real time, and make transfers seamlessly across banks and e-Wallets, all within a secure and inclusive ecosystem, at zero cost. It's about making everyday business simpler so they can focus on growing.' Meanwhile, Fuziah noted that the launch of the Business Account by TNG Digital is a new product that will add value to the MSME community in the country. 'What we are witnessing is an important step towards creating a more accessible system, especially for those who have previously been left out of the benefits of digital services,' she remarked. 'Initiatives like this are not just about technology, but also about ensuring that everyone has the opportunity to participate in and benefit from the growth of the new economy.' In addition to enabling payments, the Business Account gives merchants access to business growth tools. With over 23 million verified users on the TNG e-Wallet platform, merchants can boost visibility through features like Near Me, and drive customer engagement using GOyangGOyang cashback and voucher campaigns. The account also includes built-in safety features such as a dedicated PIN, kill switch, and 24/7 fraud protection. Looking ahead, TNG Digital plans to expand the offering into a broader ecosystem that includes micro-lending, savings, and protection services tailored for micro and small businesses. The TNG Digital Business Account reflects the company's broader mission to make business easy, so every dream, no matter how small, has the chance to grow. To learn more about TNG Digital Business Account and how it can support your business growth, visit . ‒ June 19, 2025
Geek Tyrant
6 days ago
- Entertainment
- Geek Tyrant
Video Explores The Episode That Defines STAR TREK: THE NEXT GENERATION — GeekTyrant
Filmmaker Andrew Muir, known for his YouTube channel The Art of Storytelling, has released a thoughtful new video exploring an episode that many fans say defines Star Trek: The Next Generation : Season 5's 'Darmok.' In the video, Muir dives into why this episode, centered on communication, metaphor, and mutual understanding, and how it stands out among the franchise's most meaningful. 'I recently asked my audience which episodes of 'Star Trek the Next Generation' they considered to be the best. And one of the titles that consistently came up was 'Darmok'. I found it interesting that of all the great episodes in this series …people chose a story about language as their favorite.' 'Darmok' follows Captain Picard as he's transported to a planet alongside the Tamarian captain Dathon, whose people speak exclusively in metaphor, cultural references that the universal translator can't decode. What starts as a confusing and seemingly hostile encounter slowly shifts into something much deeper. 'Tamrians speak primarily in metaphor using proper nouns to reference specific people and places that the translator has no context for. The Tamrians, frustrated by the failed discussion, decide to transport both captains to the surface of a nearby planet. 'The Tamrian captain Dayan has two blades so Picard naturally assumes this is a duel. But it soon becomes apparent that Dayan has something else in mind and it's not aggressive… it's revealed that there's some kind of predator-like beast that's hunting Picard and Dayan. So Picard finally accepts the blade, but it's too late.' Muir breaks down how the episode is about empathy, effort, and the limits of technology in truly understanding someone else's experience. It's that struggle and eventual connection that makes 'Darmok' resonate so strongly, even decades later.
Yahoo
13-06-2025
- Business
- Yahoo
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
Strasbourg (France), June 13, 2025, 8:30 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors, scientists and leaders of the biotechnology ecosystem during the upcoming editions of: BIO International Convention 2025, on June 16, in Boston, US; Portzamparc – 2025 Mid&Small Caps Conference (hosted by BNP Paribas Group), on June 18, in Paris, France; International Neoantigen Summit, on June 24, 2025, in Amsterdam, Netherlands; International Academy of Oral Oncology 2025 (IAOO), on July 18, in Liverpool, UK. Following the positive clinical data on our individualized neoantigen cancer vaccine TG4050, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here), Transgene together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology), have discussed the data presented, the unmet medical need and current treatment landscape for patients suffering from head and neck cancers in a virtual event available on Transgene website and here. *** About TransgeneTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic information about Transgene is available at: us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Media: Investors & Analysts: Caroline Tosch Lucie Larguier Corporate and Scientific Communications Manager Chief Financial Officer (CFO) +33 (0)3 68 33 27 38 Nadege Bartoli communication@ Investor Relations Analystand Financial Communications Officer MEDiSTRAVA +33 (0)3 88 27 91 00/03 Frazer Hall/Sylvie Berrebi investorrelations@ + 44 (0)203 928 6900 transgene@ DisclaimerThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250613_Transgene_Upcoming_Events_ENSign in to access your portfolio
Scottish Sun
10-06-2025
- Entertainment
- Scottish Sun
Shamed Huw Edwards' divorce delayed as he's forced to slash £750k from asking price for his family home
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) SHAMED BBC anchorman Huw Edwards' divorce has been delayed as the asking price for his family home was slashed by £750,000. His TV producer wife Vicky Flind filed for divorce days after he admitted possessing indecent images of children. Their six-bedroom detached mansion in Dulwich, south London was then put up for sale for £4.75 million last October following the couple's split. 3 Edwards' wife Vicky Flind filed for divorce days after his child sex image confession Credit: �nobledraperpictures 3 Shamed BBC presenter Huw Edwards' divorce has stalled after £750k was knocked off the asking price of his family home Credit: Alamy 3 The couple's six-bed Dulwich mansion was listed for £4.75m last October after their split Credit: Pedder/TNG But no buyers have come forward to take on the plush property amid fears it has been blighted by its links to the telly paedo. The property has attracted so little interest that online site Zoopla is still urging 'be one of the first to view' - nine months after it went on sale. Agents reduced its asking price by £250,000 in February - but a further £500,000 has now been hacked off as the couple attempt to accelerate their split. The couple bought the six-bedroom home for £1.85 million in 2006 and it is mortgage-free - and 63-year-old Edwards expected to rake in more than £2 million from his share of the sale. But the plummeting price means the presenter - who earned £475,000 at the peak of his career - has already lost more than £300,000 he hoped to rake in last year. He did not pay back £200,000 in wages funded by licence payers which he earned between his arrest over child sex charges and his resignation. Court records obtained by The Sun confirm that no decree absolute had been granted to end his 32-year marriage up to June 5. It was unclear whether property sale problems were affecting the divorce - which had been expected to have been finalised by February this year Edwards, 62, pleaded guilty in September to three charges of making indecent images of children and was given a six-month suspended jail term. EXC Shamed Huw Edwards seen for first time since paedo conviction as we reveal he hasn't returned any of his £200k BBC wage The material included abuse videos of children as young as seven, which he received via WhatsApp between December 2020 and August 2021. Ms Flind initially stood by her husband but asked him to leave the family home after his arrest. He has since been living between a flat in Wandsworth, south-west London, and a property in Carmarthen, Wales. His Dulwich home is described by the estate agent as 'a substantial detached mid-century family house' with 'exceptionally spacious living accommodation'. It features three bathrooms, three reception rooms, a library, an office, a double-length garage, and mature gardens with decking. The agency said it sits 'on one of Dulwich's most desirable residential roads'. The couple, who married in 1993, have three sons and two daughters.
Yahoo
03-06-2025
- Business
- Yahoo
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
Strasbourg (France), June 3, 2025, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced it will host a live webcast to discuss the latest positive clinical data from its individualized neoantigen cancer vaccine, TG4050, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (see press release here). The webcast will take place on June 6, 2025 at 9:00 a.m. ET / 3:00 p.m. CET, and will feature Transgene's management together with Prof. Christian Ottensmeier, MD, PhD, FRCP (University of Liverpool, La Jolla Institute for Immunology). They will discuss the new findings, the unmet medical need and the current treatment landscape and perspectives for early-stage HPV-negative head and neck cancer. Webcast link to English language conference call: Please log in to the following link to obtain your personal telephone IDs: A replay of the call will be available on the Transgene website ( following the live event. *** About TransgeneTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company's clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the myvac® platform is the Company's lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The portfolio also includes other viral-vector-based immunotherapies: TG4001 for the treatment of HPV-positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the viral backbone. The Company also conducts innovative discovery and preclinical work, aimed at developing novel viral vector-based modalities. With Transgene's myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner its proprietary platform Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic information about Transgene is available at: us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene Contacts Media: Investors & Analysts: Caroline Tosch Lucie Larguier Corporate and Scientific Communications Manager Chief Financial Officer (CFO) +33 (0)3 68 33 27 38 Nadege Bartoli communication@ Investor Relations Analystand Financial Communications Officer MEDiSTRAVA +33 (0)3 88 27 91 00/03 Frazer Hall/Sylvie Berrebi investorrelations@ + 44 (0)203 928 6900 transgene@ DisclaimerThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque') section of the Universal Registration Document, available on the AMF website ( or on Transgene's website ( Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future. Attachment 20250603_Transgene_Webcast_ENError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
